LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "oga" as a keyword



Bicyclic Picomolar OGA Inhibitors Enable Chemoproteomic Mapping of Its Endogenous Post-translational Modifications.

Sign Up to like & get
recommendations! Published in 2022 at "Journal of the American Chemical Society"

DOI: 10.1021/jacs.1c10504

Abstract: Owing to its roles in human health and disease, the modification of nuclear, cytoplasmic, and mitochondrial proteins with O-linked N-acetylglucosamine residues (O-GlcNAc) has emerged as a topic of great interest. Despite the presence of O-GlcNAc… read more here.

Keywords: translational modifications; post translational; oga; bicyclic picomolar ... See more keywords

Transcriptional Control of Gene Expression By O-Glcnacylation during Erythropoiesis

Sign Up to like & get
recommendations! Published in 2024 at "Blood"

DOI: 10.1182/blood-2024-201756

Abstract: Understanding the pathophysiological defects during erythropoiesis resulting in sickle cell disease, thalassemias, and other hemoglobinopathies is critical to the discovery of targeted therapies or cures. An understudied aspect of these disorders is how post-translational modifications… read more here.

Keywords: glcnacylation; oga; chd4; erythropoiesis ... See more keywords

Landscape of innate and adaptive immunity targets in oesophagogastric adenocarcinoma (OGA).

Sign Up to like & get
recommendations! Published in 2019 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2019.37.15_suppl.4063

Abstract: 4063 Background: Anti-PD-1 therapy modestly improves survival in chemorefractory OGA. Combining PD-1 blockade with novel checkpoint inhibitors, T-cell co-stimulatory molecules, or myeloid suppressors could enhance PD-1 inhibition. Herein, we explore the landscape of known targetable… read more here.

Keywords: expression; oga; landscape innate; innate adaptive ... See more keywords

Perioperative FLOT plus anti-PD-L1 avelumab (FLOT-A) in resectable oesophagogastric adenocarcinoma (OGA): Interim safety analysis results from the ICONIC trial.

Sign Up to like & get
recommendations! Published in 2021 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2021.39.3_suppl.201

Abstract: 201Background: ICONIC is a single-arm phase II trial investigating the safety and efficacy of perioperative FLOT-A in resectable OGA. Following a 3+3 design safety run-in phase, standard dose FLOT ... read more here.

Keywords: oga; flot resectable; perioperative flot; trial ... See more keywords